Clinical trials: Metastatic Hepatocellular Carcinoma, open to volunteers
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05168163
- Testing
- Atezolizumab, Cabozantinib, Lenvatinib
- Where
- 16 sites in United States
- Volunteers
- 122 people
- Sponsor
- Academic and Community Cancer Research United
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the…
- Conditions
- Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma
- Trial name
- NCT05092373
- Testing
- Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma
- Trial name
- NCT05705492
- Testing
- Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Hepatic Cancer, Hepatocellular Carcinoma
Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy
How to accurately and safely evaluate regional liver function before hepatectomy remains an important unsolved problem in the surgical management of hepatocellular carcinoma (HCC).
- Conditions
- Hepatic Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704203
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepatoblastoma, Hepatocellular Carcinoma (HCC)
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are…
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- ARYA-2 (NCT04634357)
- Testing
- ET140203 T Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eureka Therapeutics Inc.
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
This clinical trial compares two different kinds of surgical closing techniques, short stitch suture or traditional suture, in patients who are having liver tumor surgery.
- Conditions
- Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
- Trial name
- NCT04982653
- Testing
- Quality-of-Life Assessment, Surgical Procedure
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Malignant Tumors, Cholangiocarcinoma Metastatic
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies.
- Conditions
- Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
- Trial name
- NCT05053555
- Testing
- high dose rate brachytherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Liver Cancer, Hepatocellular Carcinoma
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer
- Trial name
- NCT06852820
- Testing
- Lu-PSMA-617
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melissa Lumish
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer.
- Conditions
- Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
- Trial name
- NCT02174549
- Testing
- Tirapazamine, Conventional Transarterial Embolization (TAE)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Teclison Ltd.
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC)…
- Trial name
- NCT06553885
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech